Muhammet Celik

Dr. Muhammet Celik

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MCMuhammet Celik
Muhammet Celik
MGMark Gold
Mark Gold
BFBrian Fuehrlein
Brian Fuehrlein
Alcohol use disorder (AUD) is a significant contributor to morbidity and mortality in the United States. It contributes to over 140,000 annual deaths, to over 200 related diseases and health conditions globally, and accounts for 5.1% of the global disease burden. Despite its substantial impact, AUD remains undertreated, marked by a scarcity of approved medications. This paper explores the current treatment landscape and novel strategies for both alcohol withdrawal syndrome and AUD. Promising results, including the use of psychedelics alongside psychotherapy, noninvasive neural-circuit-based interventions, phosphodiesterase-4 inhibitors, and GLP-1 receptor agonists, have emerged from recent studies. While these advancements show potential, further research is crucial for a comprehensive understanding of their effectiveness. The clear shortage of approved medications and other treatment modalities underscores the pressing need for ongoing research.

29 September 2022 in ImmunoTargets and Therapy
Verified
Journal Article
Open access
PDF file
MCMuhammet Celik
Muhammet Celik
BFBrian Fuehrlein
Brian Fuehrlein
Substance use disorders (SUDs) have been a major public health challenge for decades and continue to cause significant morbidity and mortality worldwide. Due to limitations in pharmacologic treatment options, there remains a significant need for the development of novel immunotherapeutic approaches. In this review, we discuss the therapeutic potential of vaccines for SUDs. Although early preclinical animal studies were optimistic and successful, few vaccines have reached human clinical trials. Only nicotine and cocaine vaccines have successfully advanced to Phase 3 clinical trials and neither are currently available as a treatment option. Various innovative approaches in vaccine design have been made to overcome limitations and improve immunogenicity, including the use of nanoparticles, synthetic haptens, and more immunogenic adjuvants. While success has thus far been elusive, with substantial scientific advancements in vaccine technology, immunotherapy remains a promising and viable option for the treatment of SUDs.

10 July 2023 in Sleep Health
Verified
Journal Article
Closed access
MCMuhammet Celik
Muhammet Celik
DCDanielle Cosentino
Danielle Cosentino
BFBrian Fuehrlein
Brian Fuehrlein

9 October 2025 in Journal of Addictive Diseases
Verified
Journal Article
Closed access
MCMuhammet Celik
Muhammet Celik
RHRyan Harrington
Ryan Harrington
CAChristopher Aloezos
Christopher Aloezos
Benzodiazepines are widely prescribed, yet their long-term use among patients with substance-use disorders (SUDs) remains poorly understood. This study examined benzodiazepines in a substance use treatment program. This study aims to describe prescribing patterns, tapering and discontinuation characteristics, and return to use rates in SUD patients receiving benzodiazepines in a community-based outpatient substance use treatment program. In this single-site, retrospective chart review study, electronic health records of 51 patients, prescribed benzodiazepines between FY 2014-2024, in a community-based outpatient substance use treatment program were analyzed. Demographics, psychiatric and SUD diagnoses, benzodiazepine half-life, dose, taper duration, discontinuation status, and return to use were examined descriptively. Intermediate-acting BZDs were the most commonly prescribed (68.6%), with limited attempts to switch to longer-acting agents. BZD prescriptions were discontinued in only 25.4% of cases, and 38.4% of those who discontinued returned to use. Patients who successfully tapered had longer down-titration durations compared to those who returned to use. (5.4 months vs. 2.2 months in return to use cases). Among patients with benzodiazepine use disorder, return to use occurred in 50.0% of those who discontinued. The patient population demonstrated notably high rates of psychiatric comorbidities and previous psychiatric hospitalizations. In patients with SUDs, benzodiazepine discontinuation is uncommon and frequently followed by return to use. Brief tapers show little benefit. Our data support that successful BZD tapering may require prolonged, structured tapering within integrated mental-health and substance use care to minimize return to use.

25 January 2024 in The American Journal on Addictions
Verified
Journal Article
Closed access
MCMuhammet Celik
Muhammet Celik
DCDanielle Cosentino
Danielle Cosentino
BFBrian Fuehrlein
Brian Fuehrlein

7 March 2025 in Journal of Addiction Medicine
Verified
Journal Article
Closed access
MCMuhammet Celik
Muhammet Celik
EZEliza Lmsw Zimmerer
Eliza Lmsw Zimmerer
BMBrittany Crc Maxwell
Brittany Crc Maxwell
CAChristopher Aloezos
Christopher Aloezos
Fentanyl, a potent synthetic opioid, has been linked to an increasing number of overdose deaths in the United States. It began replacing heroin in the illicit drug supply in 2013, and now contributes to both drug-related criminal offenses and the need for treatment. Its unique pharmacokinetics complicate the role of drug testing, which is a ubiquitous practice in both criminal justice and treatment settings. Still, there exists no clear consensus on the role of drug testing in clinical practice for patients involved in the criminal justice system. In this case report, we describe an adult female patient in outpatient addiction treatment for opioid use disorder who self-reported fentanyl abstinence while receiving medication for addiction treatment. The patient’s drug test results remained positive for fentanyl and its metabolite, norfentanyl, for 95 days and 245 days. This case illustrates the challenges of relying on drug testing in the treatment of substance use disorders due to the lack of definitive interpretation guidelines for drug levels. In addition, it highlights the importance of advocacy and collaboration between treatment providers and third-party legal entities. It may provide guidance on the role of urine drug testing in substance use treatment, particularly for emerging substances with largely unknown metabolic properties.